middle.news
How Clinuvel’s 8% Revenue Growth Fuels Vitiligo Trial and US Expansion
2:28am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Clinuvel’s 8% Revenue Growth Fuels Vitiligo Trial and US Expansion
2:28am on Saturday 30th of August, 2025 AEST
Key Points
8% increase in revenue to A$95 million
2% rise in net profit after tax to A$36.2 million
104 Specialty Centers operational in North America
Phase III vitiligo study (CUV105) recruitment completed
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CLINUVEL PHARMACEUTICALS (ASX:CUV)
OPEN ARTICLE